Physician profile
Ashley Abide Jeter
NPI 1053518555
$14,819.37
in general payments reported to CMS, 2019-2025
64 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $1,846 · 2021: $2,132 · 2022: $2,647 · 2023: $2,471 · 2024: $2,283 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,678.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,343.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,273.86 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $1,186.74 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $1,116.26 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $754.58 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Astrazeneca Pharmaceuticals LP | $687.60 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Amgen INC. | $657.70 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Incyte Corporation | $559.07 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Genzyme Corporation | $524.40 | 2019-2024 | |
| Pfizer INC. | $448.05 | 2019-2025 | |
| Seagen INC. | $377.16 | 2020-2023 | Padcev, Tukysa, Adcetris |
| Glaxosmithkline, LLC. | $363.94 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $345.20 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $341.32 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $303.50 | 2019-2025 | Phesgo, Venclexta, Tecentriq |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $302.34 | 2020-2025 | |
| Astellas Pharma US INC | $291.69 | 2019-2025 | Xtandi, Cresemba |
| Takeda Pharmaceuticals U.S.A., INC. | $275.19 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Eisai INC. | $275.08 | 2019-2024 | |
| Lilly USA, LLC | $270.70 | 2019-2025 | Verzenio, Jaypirca |
| Rigel Pharmaceuticals, INC. | $245.08 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Kite Pharma, INC. | $222.65 | 2020-2025 | Yescarta |
| Puma Biotechnology, INC. | $173.41 | 2019-2025 | |
| Abbvie INC. | $171.13 | 2019-2025 | |
| Daiichi Sankyo INC. | $153.44 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Regeneron Healthcare Solutions, INC. | $147.42 | 2019-2025 | Libtayo |
| Exelixis INC. | $134.96 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $123.66 | 2019-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $115.63 | 2020-2025 | Xpovio |
| Emd Serono, INC. | $106.35 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $103.41 | 2022-2024 | |
| Deciphera Pharmaceuticals INC. | $96.89 | 2020-2025 | Qinlock, Tgct |
| Adaptive Biotechnologies Corporation | $95.11 | 2022-2023 | Clonoseq |
| Tersera Therapeutics LLC | $85.35 | 2021-2025 | Xermelo |
| Stemline Therapeutics INC. | $79.43 | 2023-2025 | Orserdu, Elzonris |
| Beigene USA, INC. | $78.95 | 2020-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $70.68 | 2019-2022 | |
| Acrotech Biopharma INC. | $67.16 | 2021-2024 | Beleodaq |
| Morphosys, US INC. | $65.72 | 2021-2023 | Monjuvi |
| Sobi, INC | $64.47 | 2024-2025 | |
| Taiho Oncology, INC. | $59.58 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.21 | 2025 | |
| Heron Therapeutics, INC. | $53.83 | 2019 | |
| Novocure INC. | $51.16 | 2021-2024 | Optune Lua (Novottf-200t) |
| Kyowa Kirin, INC. | $46.97 | 2019 | |
| Mirati Therapeutics, INC. | $45.06 | 2023 | Krazati |
| G1 Therapeutics, INC. | $42.49 | 2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $35.97 | 2021-2024 | Ultomiris |
| Adc Therapeutics America, INC. | $35.32 | 2024-2025 | |
| Epizyme, INC. | $34.60 | 2022 | |
| Dova Pharmaceuticals | $34.38 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $27.96 | 2024 | Onivyde, Somatuline Depot |
| Fennec Pharmaceuticals, INC. | $24.46 | 2024 | Pedmark |
| Eusa Pharma (US) LLC | $24.38 | 2020 | |
| Cti Biopharma Corp. | $18.09 | 2022 | |
| Beone Medicines USA, INC. | $17.04 | 2025 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $16.28 | 2024 | Empaveli |
| Acceleron Pharma, INC. | $15.95 | 2020 | |
| Mylan Institutional INC. | $15.38 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.80 | 2020 | |
| Aurobindo Pharma USA, INC. | $14.65 | 2020 | |
| Sumitomo Pharma America, INC. | $14.21 | 2023 | Orgovyx |
| Myovant Sciences INC. | $13.92 | 2021 | |
| Clovis Oncology, INC. | $9.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Jeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.